Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Investigational Stem Cell Therapy for Hemophilia A

Dual Designations Affirm Significant Unmet Need; Multi-Year Phase 1 Data Published in the New England Journal of Medicine Underpin Advancement to Phase 2 ATLANTA, April 29, 2026 /PRNewswire/ -- Expression Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a curative...